Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cur18 is a next-generation curcumin-based nutraceutical supplement developed by Cosmos Health as part of its '18 Series' product line. It is formulated with a patented, turmeric-derived whole-spectrum extract that is standardized to approximately 50% curcuminoids and derived approximately 98.5% from turmeric, preserving the plant's natural matrix of curcuminoids, essential oils, and polar resins. This unique formulation enhances the absorption and bioavailability of curcumin through improved dispersion mechanisms. In a randomized, double-blind crossover pharmacokinetic study, Cur18 demonstrated up to 39-fold higher free curcumin bioavailability and 49.5-fold higher total curcumin AUC compared to standard 95% curcuminoid extracts. It is indicated for joint health, antioxidant support, and inflammation and mobility management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cur18.